Biopharmaceutical researchers work every day to translate science into new treatments and cures. This passion has led to breakthroughs like gene therapy to treat childhood blindness, immuno-oncology that seeks to harness the immune system’s power to eliminate cancer or slow its growth and therapies that can prevent HIV infection. The biopharmaceutical industry is also a key economic driver and supports more than four million high-skilled jobs, serving as the single largest funder of business research and development in the U.S.
To help spotlight this innovation, today, more than 60 biopharmaceutical researchers from 24 PhRMA member companies are headed to Capitol Hill in Washington, D.C. to tell the story of research and development necessary to develop new medicines for patients. In this unique moment in biopharmaceutical science, conversations on the Hill will center on the complexity of research and the importance of securing a policy environment that allows innovation to flourish. It’s critical policymakers also protect innovation from harmful proposals that seek to jeopardize our ability to continue researching and developing new medicines and patients’ access to the latest treatments.
In addition to meetings on Capitol Hill, the following day, Wednesday, May 1, we will continue the conversion by hosting an event titled, “The Future of Science: How Women are Leading Medical Innovation.”
The event will feature a panel discussion about what the new era of medicine means for women’s health, how the biopharmaceutical industry is empowering women and girls in science, technology, engineering and math (STEM) programs and what the future of science will look like. From 1990 to 2016, the share of women in the life sciences industry increased from 34 to 47 percent.
A diverse talent pool of STEM-literate Americans prepared for the jobs of the future will be essential for maintaining the national innovation base that supports key sectors of the economy and for making the scientific discoveries and developing new treatments and cures. While challenges remain to engage, attract, and support girls and women in STEM education and careers, the biopharmaceutical and broader life-sciences industries has made progress in closing STEM gaps and is focused on increasing diversity, equity and inclusion in STEM.
To learn more about the speakers and attend the event, click here.
Lori M. Reilly, Esq.
Lori M. Reilly is chief operating officer at PhRMA, providing executive level management, leadership and strategic direction for the organization. In this role, Reilly oversees PhRMA’s advocacy activities, including its federal, state and international government affairs and alliance development work. Reilly provides strategic leadership and works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients.
Reilly, named by the Washingtonian as one of the 250 most influential people in D.C., has a long record of working with members of Congress on a bipartisan basis and collaborating with stakeholders across the health care industry. Reilly is a frequent presenter on industry-related issues, including testifying before Congress on multiple occasions.
Reilly has over two decades of experience at PhRMA; prior to her current role, Reilly was the executive vice president of policy, research and membership at PhRMA, leading the development and implementation of legislative, regulatory and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee.
Reilly received a B.A. in political science from the University of Nebraska-Lincoln where she graduated with honors, and a J.D. from the University of Nebraska College of Law. She currently resides in Alexandria, Virginia with her husband and their four children.
Lori Reilly
https://www.linkedin.com/in/lorireillyphrma/
Chief Operating Officer
Celebrating STEM Day: Investing in America’s innovators
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Report: More than 1,300 medicines and vaccines in development to help fight cancer
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
New report explores setbacks that bring future cancer success stories
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Nearly 140 medicines in development to treat mental illness
New report finds 15 new oncology therapies launched last year
Clinical Trials Awareness Week: Celebrating innovation in clinical research
New Report: Advanced manufacturing powering innovative biopharmaceuticals
Guest Post: The importance of women, diversity and inclusion in STEM
New report shows more than 160 medicines in development for diabetes and related conditions
Minority health matters
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
Disrupting Alzheimer's
Aspen Spotlight Health: Discussing the forefront of innovation
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Rare Disease Day: Unmet need inspires innovation
ICYMI: Why 2017 medicine approvals matter
New report and event examine the new era of vaccines
A new era in cancer
How biopharmaceutical collaboration is driving a new era of medicine
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
Finding cures for incurable diseases
New report portrays flourishing pipeline
Going boldly together: New advancements and new anniversaries
Examining the brain in The New Era of Medicine
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
ICYMI: New era of medicine initiative kicks off in Boston
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
The 20-year journey yielding a new weapon against cancer
Event: New era of medicine comes to Capitol Hill
New Era of Medicine
STEM
Event: New era of medicine comes to Capitol Hill
Event: New era of medicine comes to Capitol Hill